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Abstract
Introduction:  Venous  thromboembolism  (VTE)  is a  relatively  common  complication  during  hos-
pital stay  and  determination  of  VTE  risk  is  critical  to  choosing  the  best  prophylactic  strategy
for each  patient.
Objectives:  In  the  present  study  we  studied  the  risk proﬁle  for  VTE  in hospitalized  patients  in
a group  of  hospitals  in  Portugal.
Methods:  Based  on an  open  cohort  of  4248  patients  hospitalized  in surgical,  internal  medicine,
orthopedic  or  oncology  departments,  we  determined  thromboembolic  risk  at  admission
by applying  a  new  score,  modiﬁed  from  the  Caprini  and  Khorana  scores.  Thrombotic,  embolic
and bleeding  events  and  death  were  assessed  during  hospital  stay  and  at  three  and  six  months
after  discharge.
Results:  The  median  duration  of  hospital  stay  was  ﬁve  days  and  thromboembolic  prophylaxis
was implemented  in 67.2%  (n=2747)  of  the  patients.  A low  molecular  weight  heparin  was  used
as prophylaxis  in the majority  of  cases  (88.3%).  Most  patients  were  classiﬁed  as  high  (68%)
or intermediate  risk  (27%).  The  overall  incidence  of  thromboembolic  events  was  1.5%.  Major
bleeding events  were  recorded  in 3.89%  of  patients  and  all-cause  mortality  was  3.4%.
Conclusions:  In  this study,  we  propose  a  modiﬁed  VTE  risk  score  that  effectively  risk-stratiﬁes  a
mixed  inpatient  population  during  hospital  stay.  The  use  of  this score  may  result  in  improvement
of thromboprophylaxis  practices  in hospitals.
©  2017  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  All  rights
reserved.
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Risco  de tromboembolismo  venoso  e  tromboproﬁlaxia  nos  hospitais  portugueses  --
Estudo  ARTE
Resumo
Introduc¸ão:  O  tromboembolismo  venoso  (TEV)  é  uma  complicac¸ão  relativamente  frequente,
complica  o  internamento  hospitalar,  e  a  determinac¸ão do risco  da  ocorrência  de  TEV  é  essencial,
de molde  a  permitir  a  escolha  da  melhor  estratégia  de proﬁlaxia  para  cada  doente.
Objetivo:  Estudar  o perﬁl  de risco  para  TEV  em  doentes  hospitalizados,  num  grupo de  hospitais
de Portugal.
Métodos:  Neste  estudo,  com  a  inclusão  duma  coorte  aberta  de 4248  doentes  internados  nos
departamentos  de cirurgia,  medicina  interna,  ortopedia  ou  oncologia,  foi  determinado  na
admissão o  risco  tromboembólico  de cada  doente,  através  dum  novo  score,  modiﬁcado  dos
scores de  Caprini  e de  Khorana.  Os  eventos  trombóticos,  embólicos  e  hemorrágicos  e  morte
foram registados  durante  o internamento  e aos  três e  seis  meses  após  a  alta.
Resultados:  A  mediana  do tempo  de  internamento  foi  de cinco  dias  e  foi administrada  terapêu-
tica de  proﬁlaxia  tromboembólica  em  67,2%  (n=2747)  dos  doentes,  foi  usada  uma  heparina  de
baixo peso  molecular  em  59,3%  dos  casos.  A maior  parte  dos  doentes  foi classiﬁcada  com  um
risco elevado  (68%)  ou intermédio  (27%).  A  incidência  global  de eventos  tromboembólicos  foi  de
1,5%. Foram  registados  eventos  hemorrágicos  maiores  em  3,89%  dos  doentes  e  a  mortalidade
por todas as  causas  foi de  3,4%.
Conclusões:  Neste  estudo,  os autores  propõem  um  novo  score  para  avaliac¸ão  do  risco  de  TEV
que estratiﬁcou  de  modo  efetivo  uma  populac¸ão  mista  de doentes  durante  o internamento
hospitalar.  O  uso  desse  score  poderá  resultar  numa  melhoria  da  prática  da  tromboproﬁlaxia  nos
nossos hospitais.
©  2017  Sociedade  Portuguesa  de Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Todos  os
direitos reservados.
Introduction
Venous  thromboembolism  (VTE),  including  deep  vein  throm-
bosis  (DVT)  and  pulmonary  embolism  (PE),  is  the third
most  common  cardiovascular  disease,  affecting  1-2  per  1000
adults  annually.1 The  disease’s  consequences  are signiﬁcant
and  can  be  incapacitating,  including  morbidity,  mortal-
ity,  disability,  and diminished  health-related  quality  of  life
among  affected  individuals,1--3 as  well  as imposing  a  substan-
tial  socioeconomic  burden  on  healthcare  systems.4 Mortality
in  patients  with  untreated  or  undiagnosed  PE  has been
reported  to  be  as  high  as  30%,5 and  it is the  third  most
common  cause  of hospital-related  death.6,7
While  vascular  endothelial  damage,  blood  ﬂow  stasis,
and  hypercoagulability  have  been  described  as  the  three
main  components  in the pathogenesis  of  venous  thrombosis,
advances  in research  have  also  identiﬁed  many  other
transient  and  persistent  risk  factors  --  demographic  (e.g.
advanced  age),  biological  (e.g.  increased  prothrombin  and
ﬁbrinogen  levels),  behavioral  (e.g.  smoking),  environmental
(e.g.  long-distance  travel),  and  health  condition-related
(e.g.  surgical  and  comorbid  conditions,  such  as  hyperten-
sion,  diabetes  or  high  cholesterol  levels)  --  that  interact
simultaneously  or  sequentially  in the development  of
VTE.8--10
VTE  is  of special  concern  in hospitalized  patients.11--13
According  to  the  current  American  College  of Chest
Physicians  (ACCP)14 and  European  Society  of Cardiology15
guidelines,  it requires  acute  treatment  with  low molecular
weight  heparin  (LMWH)  or  novel  oral anticoagulants  (NOACs)
followed  by  at  least  three  months  of  therapy  with  oral anti-
coagulants  such as  vitamin  K  antagonists  or  NOACs.  This
is  a fairly  effective  treatment  strategy  for  preventing  VTE
recurrence.
Assessment  of VTE  risk  is  essential  to  accurately  iden-
tify  patients  who  might  beneﬁt  from  VTE  prophylaxis  and
to  develop  prevention  strategies  for  optimal  care. Although
effective  VTE  prophylaxis  can  halve  the risk  of VTE,16 it is
still  largely  underused  in medical  and surgical  patients.17 In
a  population-based  study,18 of all cases  with  venous  throm-
boembolism,  24%  had  been  previously  admitted  to  a  surgical
ward  and  22%  to  a medical  ward.
Several  clinical  studies  have shown  the need  to put  into
practice  effective  hospital  strategies  based on  systematic
and  individualized  assessment  of  VTE,  and  also  to  optimize
the  institution  of proper  prophylaxis  in the context  of in-
hospital  and  outpatient  management.
Information  on  VTE  risk  and  prophylaxis  practices  in Por-
tugal  is  scarce.  Hence,  the  primary  aim  of  this study  was
to  assess  the  incidence  of VTE  risk  in the  hospital  care  set-
ting  in Portugal  using  a thromboembolic  score based  on  a
risk  assessment  model  (RAM),  adapted  from  Caprini  et  al.19
and Khorana  et al.,20 whenever  applicable  (hereafter  the
ARTE-RAM  score) (Table  1).
Secondary  objectives  were  to characterize  the proﬁle  of
patients  at risk  for  VTE,  to  determine  the  proportion  of
at-risk  patients  who  receive  effective  prophylaxis  (during
hospitalization  and  after discharge),  and  to  determine  the
incidence  of  thromboembolic  and bleeding  events  (during
hospitalization  and after  discharge).
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Table  1  Risk  factors  and  corresponding  point  count  for
calculation  of  the  ARTE-RAM  thromboembolic  risk  score
(adapted  from  Caprini  et al.19 and  Khorana  et  al.20).
Risk  factor Points
Age  40-60  years  1
Obesity  (BMI  >30  kg/m2) 1
Major surgery  (<1  month)  1
Varicose  veins  1
Smoking  1
CHF (present  or  <1  month) 1
Sepsis  or  severe  infection  (<1  month) 1
Acute pulmonary  disease  1
COPD 1
Inﬂammatory  bowel  disease  1
Oral contraception  or  HRT  1
Pregnancy  or  postpartum  (<1  month) 1
History  of  unexplained  stillborn  infant,
miscarriage,  premature  birth  with  toxemia
or  growth-restricted  infant
1
Minor  surgery  1
Lung tumor  1
Lymphoma  1
Gynecologic  cancer  1
Genitourinary  or  prostate  cancer  1
Platelet  count  before  chemotherapy
≤350  000/l
1
Hemoglobin  <10  g/dl  or  RhEPO  use  1
Leukocyte  count  before  chemotherapy
>11 000/mm3
1
Medical patient  currently  at  bed  rest  1
Age 61-74  years  2
BMI >35  kg/m2 2
Cancer (active  or previous)  2
Patient conﬁned  to  bed  (>72  h) 2
Immobilization  2
Central  venous  access  2
Major surgery  (>45  min) 2
Laparoscopic  surgery  2
Arthroscopic  surgery 2
Gastric  tumor  2
Pancreatic  tumor  2
Age >74  years 3
History  of  DVT  3
Thrombophilia  (per  type)  3
Family history  of  DVT  3
Stroke (<1  month)  5
Major lower  limb  arthroplasty  5
Pelvic,  hip  or  leg  fracture  (<1  month)  5
Acute spinal  cord  injury  (paralysis)  (<1 month)  5
Multiple trauma  (<1  month)  5
BMI: body mass index; CHF: congestive heart failure; COPD:
chronic obstructive pulmonary disease; DVT: deep vein throm-
bosis; HRT: hormone replacement therapy; RhEPO: recombinant
human erythropoietin.
Methods
The  detailed  methodology  of  the  ARTE  (Avaliac¸ão  de
Risco  de  Tromboembolismo  Venoso  --  Assessment  of
Venous  Thromboembolism  Risk)  study has  been  previously
published.21 Brieﬂy,  ARTE  was  a non-interventional,  multi-
center,  prospective  study  performed  from  December  2008  to
June  2012  at 14  Portuguese  hospitals  (listed  in the  Acknowl-
edgements  section).  Inclusion  criteria  were  patients  aged
≥18  years  hospitalized  in  one of  the eligible  medical  depart-
ments  (internal  medicine,  oncology,  surgical  or  orthopedic),
who  signed  informed  consent  to  participate.  The  study
excluded  patients  admitted  with  a diagnosis  of  VTE,  or  who
were  receiving  chronic  antithrombotic  therapy.
Patients  were enrolled  sequentially  in each  participating
center  until  the desired  sample  size  of  4000  patients  was
achieved,  and  treated  at the physician’s  discretion  accord-
ing  to  local  clinical  practice.  Data  were  collected  from
hospital  charts  and  the  relevant  information  was  entered
onto  standardized  case  report  forms.  Patient  demograph-
ics,  admission  discharge  diagnoses,  risk  factors  for  VTE (as
deﬁned  in the  ACCP  guidelines22),  risk  factors  for  bleed-
ing,  duration  of  hospitalization,  type  of  VTE  prophylaxis
and  concomitant  medication  were obtained  directly  from
patients  at the time  of  enrollment  and of  hospital  discharge.
At  the  time  of  enrollment,  the ARTE-RAM  thromboembolic
score  was  also  calculated  for  each  patient.
In  order  to  assess  the  occurrence  of  thromboembolic  and
bleeding  events,  as  well  as  cases  of  death  or  hospital  read-
mission,  patients  were further  contacted  by telephone  at six
months  after  discharge.
Statistical  analysis
An estimated  1000  patients  were  included  per  analysis  sub-
group  to  assess  the  true  occurrence  of  VTE  risk  at a  95%
conﬁdence  interval  with  a  margin  of  error  of  3%.  Quantita-
tive  data  were  expressed  as  medians  or  means  (and  standard
deviation)  when appropriate,  while  categorical  data  were
expressed  as  number  and  percentage  of the  population.
Exploratory  analysis  was  performed  using  chi-square  testing
for  categorical  variables  and  two-sided  t  tests  for  contin-
uous  variables.  A  p-value  of  less  than  0.05  was  considered
statistically  signiﬁcant.
Results
The  number  of  patients  included  and  the  study  ﬂow  diagram
are  depicted  in  Figure  1.
A  total  of  4090  patients  were  enrolled  (54%  female),
mean  age  57  years,  mean  weight  71  kg,  mean  height
164  cm, mean  body mass  index  26.2  kg/m2,  and  17%  obese.
Patients’  demographic  and clinical  characteristics  are
shown  in Table  2.
The proportions  of patients  included  in each  of  the four
medical  areas  considered  were 38.4%  (n=1570)  in oncol-
ogy,  24.6%  (n=1008)  in general  surgery,  18.7%  (n=764)  in
internal  medicine  and  18.3%  (n=748)  in orthopedics.  Of
the  total  population,  592 patients  (14.5%)  had  a  fam-
ily  history  of  thromboembolism.  The  mean  length  of
hospital  stay  was  8.3±18.1  days (median  5),  and  the
major  reasons  for hospitalization  were  cancer  (15.0%),
gastrointestinal/hepatobiliary  disease  (8.5%)  and  acute  non-
infectious  respiratory  disease  (6.1%).  Six-month  follow-up
was  obtained  in 2923  (71.5%)  patients.
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Patients enrolled:
4090a
Discharged from hospital:
4065 (99.4%) 
Three-month follow-up:
2998 (73.8%)
Six-month follow-up:
2923 (71.5%) 
Deaths:
25 (0.6%) 
Lost to follow-up: 978 (24.1%)
Dropped out: 12 (0.3%)
Follow-up data beyond study date limit: 6 (0.1%)
Died: 70 (1.5%) 
Lost to follow-up: 38 (1.3%)
Deaths: 45 (1.5%)
Figure  1  Study  ﬂow  diagram. aOf  the total  4248  patients  originally  included,  158  were  excluded,  of  whom  63  (39.9%)  did not
fulﬁll eligibility  criteria,  44  (27.9%)  had seriously  incomplete  records,  42  (26.6%)  had  no available  weight  data,  and  nine  (5.7%)  had
no available  hospital  discharge  and/or  follow-up  data.
The  incidence  of  the  ARTE-RAM  scores  obtained  at admis-
sion  in  the  overall  population  is  shown  in Table  3.
According  to  the predeﬁned  classes  of thromboembolic
risk,  192  patients  (4.7%)  were considered  to  have  low risk  for
VTE  (ARTE-RAM  score  of  0 or  1),  1090  (26.7%)  intermediate
risk  (ARTE-RAM  score  of 2,  3  or  4) and  2808  (68.6%) had  an
ARTE-RAM  score ≥5, and  were  considered  at high  risk  for
VTE.
Considering  the different  medical  areas  individually,  the
distribution  of  the  risk  classes  was  as shown  in Table  4.  A high
risk  of  VTE  (ARTE-RAM  score ≥5)  was  more  prevalent  among
oncology  patients  (88.2%),  followed  by  orthopedic  patients
(72.5%),  surgical  patients  (54.6%)  and internal  medicine
patients  (43.2%).
Overall,  2747  patients  (67.2%)  received  VTE  prophy-
laxis  during  hospitalization,  and  592  (20.3%)  of those  with
follow-up  received  VTE  prophylaxis  after  discharge.  During
hospitalization,  VTE  prophylaxis  was  most frequently  pre-
scribed  for  orthopedic  and  oncology  patients  (76.5%  and
72.0%,  respectively),  and  LMWH  was  the most  commonly
used  type  of prophylaxis  (88.3%  of  the 2747  treated  inpa-
tients),  for  a mean  of  7.8±10.6  days (median  6).  In 12.3%
(n=505)  of  the patients,  LMWH  was  maintained  after  dis-
charge  from  hospital.  Regarding  the outpatient  setting,
among  the  2923  patients  with  six-month  follow-up,  VTE  pro-
phylaxis  was  also  most frequently  recorded  in orthopedic
and  oncology  patients  (36.2%  and  14.3%,  respectively),  and
LMWH  was  also  the most commonly  prescribed  type  of  pro-
phylaxis  (85.3%  of  the 592  treated  outpatients)  (Table  5).
In  the  study  population,  59  patients  (1.4%)  had  con-
traindications  for  pharmacological  prophylaxis,  26  (44.1%)  of
whom  were  hospitalized  in internal  medicine  departments.
Even  though  contraindication  for  anticoagulation  was  identi-
ﬁed,  22  patients  received  prophylaxis  during  hospitalization,
and  three  during  follow-up.
The  overall  incidence  of thromboembolic  events  was
1.5%,  corresponding  to  60 patients,  22  (0.58%)  during  hos-
pital  stay  and  36  (0.93%)  during the six-month  follow-up
period.  The  most  common  types  of  VTE  during  hospital-
ization  were  deep  vein thrombosis  (n=10),  ischemic  stroke
(n=6)  and  pulmonary  embolism  (n=5),  and  deep  vein throm-
bosis  (n=13)  and  ischemic  stroke  (n=13)  during  follow-up.
Overall,  the majority  of VTE  occurred  in oncology  and
internal  medicine  patients  (n=29  and  n=21,  respectively).
Analysis  of  the  occurrence  of VTE  during  hospitalization  and
follow-up  periods  separately  reveals  a signiﬁcantly  greater
number  of  VTE  episodes  in  internal  medicine  patients  during
hospitalization  (n=13,  p<0.001)  and  also  more  in oncology
patients  during  follow-up  (n=21),  although  this  was  not  sta-
tistically  signiﬁcant  (p=0.055).
A  total  of  327 patients  (8%)  had  bleeding  events,  in
216  of  whom  the event  occurred  during hospitalization,
106 during follow-up,  and  ﬁve  during both  periods.  Major
bleeding  events  were  observed  in 159  (3.9%)  of hospitalized
patients,  and  in 68  (2.3%)  of  outpatients.  The  most frequent
major bleeding  events  during  hospitalization  were  ≥2  g/dl
hemoglobin  decrease  (n=142),  blood  transfusion  (n=98),
intestinal  and  gastric  bleeding  (n=17  and  n=12,  respec-
tively)  and  intestinal  bleeding  (n=63),  ≥2 g/dl  hemoglobin
decrease  (n=7)  and  blood  transfusion  (n=6)  during  follow-up.
Mortality  from  any  cause  over the six-month  study  period
was  3.4%.
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Table  2  Baseline  demographic  and  clinical  characteristics
of the  4090  patients  included.
Demographic
Female,  %  (n)  54  (2209)
Age in  years,  mean  (SD)  57  (17)
Weight in  kg,  mean  (SD) 71  (15)
BMI in  kg/m2,  mean  (SD) 26.2  (4.7)
Body mass  index  >30  kg/m2, %  (n) 17  (695)
General  aspects
Family  history  of DVT,  %  (n)  14.5  (592)
Patient conﬁned  to  bed  (>72  h),  %  (n)  16.6  (690)
Immobilization,  % (n) 8.9 (364)
Central venous  access,  %  (n) 7.7 (314)
Previous  history
Stroke  (<1  month),  %  (n)  0.9 (36)
Deep vein  thrombosis  history,  %  (n)  3.5 (144)
Cancer (active  or  previous),  %  (n)  34.6  (1,416)
Major surgery  (<1  month),  %  (n)  3.8 (156)
Varicose veins,  %  (n)  30.5  (1,248)
Smoking habits,  %  (n)  19.7  (806)
Thrombophilia  (per  type),  % (n) 0.3 (10)
Clinical  history
CHF  (present  or  <1  month),  %  (n) 6.1 (248)
Sepsis or  severe  infection  (<1  month),  %
(n)
3.7  (152)
Acute pulmonary  disease,  %  (n)  6.5 (266)
COPD, % (n)  4.1 (168)
Medical patient  currently  at bed  rest,  %
(n)
7.6  (311)
Inﬂammatory  bowel  disease,  %  (n)  1.2 (48)
Gynecological/obstetric  history
Oral  contraception  or  hormone
replacement  therapy,  %  (n)
15.7  (343)
Pregnancy  or  postpartum  (<1  month),  %
(n)
1.1  (25)
History of  unexplained  stillborn  infant,
miscarriage,  premature  birth  with
toxemia  or  growth-restricted  infant,  %  (n)
4.6  (100)
Surgical  patients
Major  surgery  (>45  min),  %  (n)  47.3  (1,935)
Laparoscopic  surgery,  %  (n) 8.2 (336)
Arthroscopic  surgery,  %  (n)  3.9 (161)
Minor elective  surgery,  %  (n)  9.9 (403)
Orthopedic  patients
Major  lower  limb  arthroplasty,  %  (n)  7.2 (294)
Pelvic, hip  or  leg  fracture  (<1  month),  %
(n)
3.3  (134)
Acute spinal  cord  injury  (paralysis)  (<1
month),  %  (n)
0.4  (18)
Multiple trauma  (<1  month),  %  (n)  0.5 (20)
Cancer patients  under  chemotherapy
Gastric  tumor,  %  (n)  9.0 (130)
Pancreatic tumor,  %  (n)  1.4 (20)
Lung tumor,  % (n) 3.9 (57)
Lymphoma,  %  (n)  1.4 (20)
Gynecologic cancer,  %  (n)  16.2  (129)
Genitourinary  or  prostate  cancer,  %  (n)  10.2  (148)
Table  2  (Continued)
Platelet  count  before  chemotherapy
≤350  000/l,  %  (n)
4.9  (71)
Hemoglobin  <10  g/dl  or  RhEPO  use,  %  (n) 6.0  (87)
Leukocyte count  before  chemotherapy
>11  000/mm3,  %  (n)
3.7  (54)
BMI: body mass index; CHF:  congestive heart failure; COPD:
chronic obstructive pulmonary disease; DVT: deep vein throm-
bosis; HRT: hormone replacement therapy; RhEPO: recombinant
human erythropoietin.
Table  3  Observed  ARTE-RAM  scores  in the overall
population.
ARTE-RAM  score  Incidence  n (%;  95%  CI)
0  48  (1.2;  0.9-1.5)
1 144  (3.5;  3.0-4.1)
2 263  (6.4;  5.7-7.2)
3 395  (9.7;  8.8-10.6)
4 432  (10.6;  9.6-11.5)
≥5  2808  (68.6;  67.2-70.1)
CI: conﬁdence interval.
Discussion
The  validation  of a  RAM  modiﬁed  from  the  Caprini  and
Khorana  scores  in a heterogeneous  hospitalized  population
that  includes  medical  and  cancer  patients  may  be useful
in  clinical  practice.  Given  the  complexity  of  a  signiﬁcant
number  of  medical  and cancer  patients,  an  ideal  model
must  accurately  identify  a  threshold  for the risk  of  VTE  and
predict  the correct  risk  level  in heterogeneous  patients  at
admission,  irrespective  of  their  initial  or  ﬁnal  diagnosis.23
One  attempt  to develop  such  a risk  score  in  patients  with
active  cancer  in  chemotherapy  was  the  Protecht  score.24
This  score  requires  a  P-selectin  assay,  which  may  limit  its
practical  use,25 and  is  only  included  here for  reasons  of
comparison.  The  ARTE-RAM  score  presented  in this study
was  based on  both  well-established  and novel  risk  factors,
aiming  for a  consensual  version  of  a tool  that  can  be widely
used  in daily  clinical  practice,  responding  to  a  perceived
need  in the  medical  community.26
The  ARTE  study,  including  populations  admitted  to  gen-
eral  surgery  and  medicine  departments,  was  designed  to
assess  a new  risk  scoring  method  and  to  demonstrate  the
value  of  individual  risk  assessment  for  a broad  range  of
patients.  The  study  was  conducted  in a cohort  of  patients
hospitalized  in four departments  (internal  medicine,  oncol-
ogy,  surgical  or  orthopedic)  of  14  hospitals  in  Portugal.
Overall,  the  study  demonstrated  a  high  prevalence  of
high  risk  for VTE  (68%  of  all  patients),  which is  considerably
higher  than the  overall  risk  for  VTE  (52.7%)  found in  the
Portuguese  patients  included  in the ENDORSE  study.27 This
difference  may  be due to  the especially  high  prevalence  of
VTE  risk  among  oncology  and orthopedic  patients  found  in
our  study.
The 67.2%  of  all  in-hospital  patients  who  received
some  kind  of  thromboprophylaxis  in  the ARTE  study  is  an
improvement  over  the  58.5%  treated  patients  found  in
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Table  4  Distribution  of  risk  classes  by  medical  area.
Risk  classes  (ARTE-RAM  score)  Incidence  n  (%)  (95%  CI)
Internal  medicine Oncology  Orthopedic  Surgical
Low  risk  (0-1)  115  (15.1)  (12.6-17.6)  13  (0.8)  (0.4-1.2)  23  (3.1)  (1.9-4.3)  41  (4.1)  (2.9-5.3)
Intermediate  risk (2-4)  319  (41.8)  (38.3-45.3)  172  (11.7)  (10.1-13.3)  182  (24.3)  (21.2-27.4)  417 (41.4)  (38.4-44.4)
High risk  (≥5)  330  (43.2)  (39.7-46.7)  1385  (88.2)  (86.6-89.7)  543  (72.5)  (69.3-75.7)  550 (54.6)  (51.5-57.6)
CI: conﬁdence interval.
Table  5  Thromboembolic  prophylaxis.
Inpatients  (n=4090)  Outpatients  with  follow-up  (n=2923)
No.  of  patients  (%)  No.  of  patients  (%)
Treated  patients 2747  67.2 592  20.3
Unfractionated heparin 18  0.4 2  0.1
LMWH 2425  59.3 505  17.2
Xa inhibitors 1  -  32  1.1
VKA 20  0.5 34  1.2
Other measures  (elastic  compression  stockings)  622 15.2  41  1.4
LMWH: low molecular weight heparin; VKA: vitamin K antagonists.
the  Portuguese  ENDORSE  subgroup,  which  may  reﬂect  an
increase  in awareness  on  this  subject.
Despite  the  variety  of  prophylaxis  measures,  45  of  the
2747  treated  patients  (1.6%)  suffered  VTE.  In a  paper  by
Zakai  et  al.,28 the incidence  of VTE  was  7.6  per  1000  admis-
sions.  If  ischemic  stroke  is  excluded,  we found  an  incidence
of  3.9  VTE  events  per  1000  admissions.  This  difference  could
be  explained  by  a  higher  percentage  of prophylaxis  in  our
study  (67.2%  vs.  52%  in  Zakai  et al).
The  ARTE  study  corroborates  other  reports29 that  alert
the  medical  community  to  the need  for  extended  VTE  pro-
phylaxis  beyond  hospital  discharge.  In fact,  the majority  of
VTE  events  were  recorded  in the six-month  follow-up  period
(0.93%  of  all  patients).
Major  bleeding  events  were  mainly  observed  during  hos-
pital  stay,  when  close  medical  vigilance  enables  immediate
intervention  to  minimize  its  consequences.  Of  inpatients
receiving  anticoagulant  prophylaxis,  only 3.89%  had  a
major  bleeding  complication.  This  underlines  the need  for
accurate  risk  estimation  before  the  introduction  of pharma-
cological  VTE  prophylaxis,  in order  to  offer  an appropriate
strategy  for  each  patient  and especially  to  avoid  underuse  of
anticoagulants  based on  wrongly  perceived  clinical  assump-
tions  of  risk  for  bleeding  complications.
Several  studies,  including  a Cochrane  review,  have eval-
uated  the  importance  of interventions  designed  to  increase
the  implementation  of  thromboprophylaxis  in hospitalized
adult  medical  and  surgical  patients.  The  Cochrane  review,
published  in  2013,30 analyzed  55  studies,  including  ran-
domized  controlled  trials  and  observational  studies,  that
implemented  a variety  of system-wide  strategies  aimed
at  improving  thromboprophylaxis  rates in many  settings
and  patient  populations.  The  authors  found statistically
signiﬁcant  improvements  in prescription  of  prophylaxis
therapies  associated  with  education,  alerts  and  multi-
faceted  interventions.  Multifaceted  interventions  with  an
alert component  seems to  be the  most  effective.  Another
review  analyzed  ambulatory  cancer  patients  receiving
chemotherapy31 and  conﬁrmed  the importance  of  primary
thromboprophylaxis  in  reducing  the  incidence  of  symp-
tomatic  VTE.
Worldwide,  the search  for cost-effective  strategies  for
prevention  of  VTE  has  been  a  fundamental  concern  in recent
years.  There  is, however,  no agreement  as  to the  best
approach  on  this  issue.  On one  hand there  is  solid  evidence
showing  the  effectiveness  of  computerized  decision  support
for the implementation  of  thromboprophylaxis.  On  the  other
hand,  there  have  been doubts  about its  cost-effectiveness.
A study  published  in 201132 assessed  a  four-year  period
in a  Spanish  hospital  and  demonstrated  that  the implemen-
tation  of  e-alerts  led  to  a  net cost  saving  of D  6.50  per
hospitalized  patient  and  concludes  that  if  all hospitalized
patients  in Spain  were  considered,  the total  yearly  savings
would  approach  D 30 million.
Limitations
This  study  has  several  limitations.  Firstly,  although  we made
an initial assessment  of  risk  factors  at time  of  admission,
identiﬁed  by  qualiﬁed  physicians,  there  may  have  been
intersite  variability  in data  collection.  Secondly,  for  the pur-
pose  of classifying  patients  in disease  categories,  we  used
the  admission  diagnosis  as  the main  diagnosis,  accepting
that, in  some  cases,  this diagnosis  could  be wrong  or  the
clinical  course  of  the  disease  episode  could  modify  the rela-
tive  effect  of  VTE  risk  factors  (for example,  a  patient  could
be admitted  for  an acute  condition  attributed  to  cancer  but
undergo  surgical  intervention  during hospital  stay). Thirdly,
clinical  diagnosis  of DVT and  PE  is  known  to  be unreliable
and  clinical  examination  alone  underestimates  the true  inci-
dence  of VTE,33 particularly  in  an  outpatient  setting,  which
may  have  contributed  to  underestimation  of  asymptomatic
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VTE  events  and  hence of  the true  incidence  of  VTE.  Finally,  a
large  number  of  patients  were  lost  to  follow-up,  hampering
analysis  of  thromboprophylaxis  and clinical  outcomes  after
hospital  discharge.
Conclusions
The  ARTE  study  demonstrated  that  a large  proportion  of
hospitalized  patients  are at high  risk  of VTE.  Thrombopro-
phylaxis  was  administered  to  a signiﬁcant  number  of these
patients  but  its  use  may  be  less  desirable  in the  outpatient
setting.  Validation  of  the ARTE-RAM  score  in  future  studies
may  support  the  ARTE  study’s  ﬁndings  and  lead  to  its  use
when  combined  with  appropriate  information  technology.
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